Extended Data Table 7 Summary of ADA after the dose of cadonilimab in combination with chemotherapy

From: Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial

  1. aBaseline-positive: participants with a positive ADA results and titer level greater than 1:8 at baseline.
  2. bNon-treatment-emergent-positive: participants without a positive ADA result at baseline but with any positive response (titer level ≤ 1:8); after receiving the treatment, OR participants with a baseline-positive ADA result in whom the assay signal was not enhanced (less than fourfold over baseline titer level) at any time after the initial drug administration.
  3. cTreatment-emergent positive: participants without a positive ADA result at baseline but with any positive response (titer level greater than 1:8); after receiving the treatment, OR participants with a baseline-positive ADA result in whom the assay signal was enhanced (greater than or equal to fourfold over the baseline titer level) at any time after receiving treatment. ADA, antidrug antibody.
Back to article page